James A. Hall
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells.
Journal: Nucleic acids research
Published: February 28, 2025
A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.
Journal: Cell reports. Medicine
Published: January 22, 2024
Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients.
Journal: Cancers
Published: April 17, 2023
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
Journal: Cancer discovery
Published: April 04, 2023
Molecular landscape and functional characterization of centrosome amplification in ovarian cancer.
Journal: Nature communications
Published: February 16, 2023
High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
Journal: eLife
Published: September 30, 2022
Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.
Journal: Cancer research communications
Published: March 17, 2022
Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.
Journal: EMBO molecular medicine
Published: January 18, 2022
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.
Journal: Nature communications
Published: December 17, 2021
Effective drug combinations in breast, colon and pancreatic cancer cells.
Journal: Nature
Published: July 02, 2021
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.
Journal: Molecular systems biology
Published: December 18, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026